RT Journal Article
T1 Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC-Spain).
A1 Lope, Virginia
A1 Castello, Adela
A1 Mena-Bravo, Antonio
A1 Amiano, Pilar
A1 Aragones, Nuria
A1 Fernandez-Villa, Tania
A1 Guevara, Marcela
A1 Dierssen-Sotos, Trinidad
A1 Fernandez-Tardon, Guillermo
A1 Castaño-Vinyals, Gemma
A1 Marcos-Gragera, Rafael
A1 Moreno, Víctor
A1 Salas-Trejo, Dolores
A1 Diaz-Santos, Marian
A1 Oribe, Madalen
A1 Romieu, Isabel
A1 Kogevinas, Manolis
A1 Priego-Capote, Feliciano
A1 Perez-Gomez, Beatriz
A1 Pollan, Marina
K1 25(OH)D
K1 Breast neoplasm
K1 Calcidiol
K1 Stage at diagnosis
K1 Triple negative tumor
K1 Vitamin D
AB Epidemiologic evidence on the association between vitamin D and breast cancer is still inconclusive. This study analyzes the association between serum 25-hydroxyvitamin D (25(OH)D) and breast cancer risk by pathologic subtype, stage at diagnosis and specific breast cancer risk factors. We conducted a population-based multicase-control study where 546 histologically-confirmed breast cancer cases and 558 population controls, frequently matched by geographic area, age and body mass index, were recruited in 12 Spanish provinces (MCC-Spain). Information was collected by a questionnaire and plasma 25(OH)D was measured by solid-phase extraction on-line coupled to liquid chromatography-tandem mass spectrometry (SPE-LC-MS/MS). Odds ratios and 95% confidence intervals were calculated using logistic and multinomial mixed regression models. We found a clear protective effect between 25(OH)D levels and breast cancer risk, with a significant dose-response trend (OR per 10 nmol/L = 0.88; 95%CI = 0.82-0.94). While no differences were observed between pre and postmenopausal women, stage at diagnosis, or across strata of the main breast cancer risk factors, the protection was more pronounced for triple negative tumors (OR per 10 nmol/L = 0.64; p-heterogeneity = 0.038). Similar results were observed when only cases sampled in the first month after diagnosis were considered. The protective effect of vitamin D on breast cancer risk may be subtype specific, being stronger for more aggressive tumors, which provides a new approach to prevent this disease.
PB Elsevier
YR 2018
FD 2018-04-13
LK http://hdl.handle.net/10668/12378
UL http://hdl.handle.net/10668/12378
LA en
NO Lope V, Castelló A, Mena-Bravo A, Amiano P, Aragonés N, Fernández-Villa T, et al. Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC-Spain). J Steroid Biochem Mol Biol. 2018 Sep;182:4-13
NO The study was funded by Carlos III Institute of Health grants (PI12/00488, PI12/00265, PI12/00715, PI12/01270, PI09/00773 and PI08/1770), by the Spanish Ministry of Health (EC11-273), by the Spanish Ministry of Economy and Competitiveness (IJCI-2014-20900) and by Consejería de Salud de la Junta de Andalucía (PI-0571-2009) competitive calls including peer review for scientific quality. Additional funding was provided by the Spanish Federation of Breast Cancer Patients (FECMA: EPY 1169-10), the Associationof Women with Breast Cancer from Elche (AMACMEC: EPY 1394/15), the Marqués de Valdecilla foundation (grant API 10/09), and by Acción Transversal del Cancer, approved by the Spanish Ministry Council onOctober 11, 2007. None of the funders played any role in conducting research or writing the paper. This article presents independent research. The views expressed are those of the authors and not necessarily those of the Carlos III Institute of Health.
DS RISalud
RD Apr 5, 2025